NCT06063317 2026-03-06
OASIS
Imugene Limited
Phase 1 Terminated
Clinical Trials
4 trialsNCT06871410 2026-01-26
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT07190833 2025-09-24
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
Phase 1 Not yet recruiting
NCT06005324 2025-06-08
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
University of Chicago
Phase 1 Recruiting